A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03522142 |
|
Recruitment Status :
Recruiting
First Posted : May 11, 2018
Last Update Posted : May 12, 2023
|
Sponsor:
Incyte Corporation
Information provided by (Responsible Party):
Incyte Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Solid Tumors | Drug: INCB081776 Drug: INCMGA00012 | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 140 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies |
| Actual Study Start Date : | August 27, 2018 |
| Estimated Primary Completion Date : | November 2, 2023 |
| Estimated Study Completion Date : | December 2, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: INCB081776
Single-agent INCB081776.
|
Drug: INCB081776
INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose. |
|
Experimental: INCB081776 + INCMGA00012
INCB081776 in combination with INCMGA00012.
|
Drug: INCB081776
INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose. Drug: INCMGA00012 INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
Other Name: retifanlimab |
Primary Outcome Measures :
- Part 1 (1A and 1B): Number of treatment-emergent adverse events (TEAEs) [ Time Frame: Screening through 90 days after end of treatment, up to approximately 1 year. ]A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.
- Part 1 (1A and 1B): Recommended Dose for Expansion (RDE) [ Time Frame: Up to one year ]Recommended dose as a monotherapy as measured by safety, PK and data
- Part 2 (2A & 2B): Number of treatment-emergent adverse events [ Time Frame: Screening through 90 days after end of treatment, up to approximately 1 year ]A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.
- Part 2 (2A & B): RDE in combination with INCMGA00012 [ Time Frame: Up to one year ]Recommended dose as a combination as measured by safety, PK and data
Secondary Outcome Measures :
- Part 1 and Part 2: Cmax of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Maximum observed plasma concentration.
- Part 1 and Part 2: Tmax of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Time to maximum plasma concentration.
- Part 1 and Part 2: t½ of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Apparent plasma terminal phase disposition half-life
- Part 1 and Part 2: Pharmacokinetic/ pharmacodynamic correlation [ Time Frame: Up to approximately 3 weeks. ]To evaluate the correlation pharmacokinetic and pharmacodynamics of INCB081176
- Part 1 and Part 2: Overall response rate [ Time Frame: Up to approximately 1 year. ]Defined as the percentage of participants having complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Part 1 and Part 2: Disease control rate [ Time Frame: Up to approximately 1 year. ]Defined as the percentage of participants having CR, PR, or stable disease (SD) per RECIST v1.1.
- Part 1 and Part 2: Duration of response [ Time Frame: Up to approximately 1 year. ]Defined as the time from earliest date of disease response until the earliest date of disease progression (per RECIST v1.1) or death due to any cause, if occurring sooner than progression.
- Part 1 and Part 2: AUC0-t of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration
- Part 1 and Part 2: Cmin of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Trough concentration of INCB081776
- Part 1 and Part 2: AUC0-∞ of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Area under the single-dose plasma concentration-time curve from Hour 0 to infinity
- Part 1 and Part 2 : CL/F of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Oral dose clearance
- Part 1 and Part 2 : λz of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Terminal elimination rate constant
- Part 1 and Part 2 : Vz/F of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]Apparent oral dose volume of distribution
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
• Male and female participants at least 18 years of age with advanced malignancies who have received or been intolerant to standard therapy:
Parts 1A and 2A:
- Histologically confirmed advanced or metastatic gastric or GEJ adenocarcinoma, HCC, melanoma, NSCLC, RCC, soft-tissue sarcoma, SCCHN (recurrent or metastatic), TNBC, or urothelial carcinoma. Additional tumor histologies, including MSI-H tumors, may be allowed with approval from the medical monitor.
- Measurable disease per RECIST v1.1.
Parts 1B and 2B:
• Histologic confirmation of the cohort-specific tumor types specified below: Cohort 1 - Advanced or metastatic melanoma Cohort 2 - Advanced or metastatic NSCLC Cohort 3 - Recurrent or metastatic SCCHN Cohort 4 - Advanced or metastatic soft-tissue sarcoma
- Cohorts 1-3 must have received 1 prior PD-1/L1 treatment and have experienced PD during or after that treatment and have progressed on other SOC therapy(ies); Cohort 4 must be PD-1/L1 treatment naïve but have progressed on SOC therapy(ies).
- Measurable disease per RECIST v1.1.
- Must be willing to submit to a fresh baseline tumor biopsy and an on-treatment biopsy between Cycle 2 Day 1 and Cycle 3 Day 1.
- Care should be taken to biopsy the same lesion for the baseline and on-treatment samples. If a participant has a solitary target lesion, this should not be biopsied.
Part 1C:
- Participants with relapsed/refractory AML following standard therapy; acute promyelocytic leukemia (M3) and therapy-related AML are excluded.
- FLT3-ITD and IDH1/2 wild-type or mutated are eligible; appropriate targeted therapy for participants with actionable mutations must have been received.
Exclusion Criteria:
- Laboratory values not within the protocol-defined range.
- History of retinal disease as defined in the protocol.
- Clinically significant cardiac disease as per protocol-defined criteria.
- History or presence of an ECG that, in the investigator's opinion, is clinically meaningful as per protocol-defined criteria.
- Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed as per protocol-defined criteria.
- Active or inactive autoimmune disease or syndrome that has required systemic treatment in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory disease.
- Prior Grade 3 or higher immune-related AEs or any ocular toxicity on prior immunotherapy as per protocol-defined criteria.
- Receipt of any vitamin K antagonists, systemic corticosteroids, live vaccines, or treatment with any anticancer medications or investigational drugs within the protocol-defined intervals.
- Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment.
- Active infection requiring systemic therapy.
- Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
- Known history of HIV (HIV 1/2 antibodies).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03522142
Contacts
| Contact: Incyte Corporation Call Center (US) | 1.855.463.3463 | medinfo@incyte.com |
Locations
Show 19 study locations
Sponsors and Collaborators
Incyte Corporation
Investigators
| Study Director: | Diane Hershock, MD | Incyte Corporation |
| Responsible Party: | Incyte Corporation |
| ClinicalTrials.gov Identifier: | NCT03522142 |
| Other Study ID Numbers: |
INCB 81776-101 |
| First Posted: | May 11, 2018 Key Record Dates |
| Last Update Posted: | May 12, 2023 |
| Last Verified: | May 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Incyte Corporation:
|
Advanced solid tumors AXL MER AXL/MER PD-1 |
Additional relevant MeSH terms:
|
Neoplasms |